LTIP829A - Derivatives of 2-amino-4-morpholino-6-propyl-1,3,5,-triazine and salts thereof - Google Patents
Derivatives of 2-amino-4-morpholino-6-propyl-1,3,5,-triazine and salts thereofInfo
- Publication number
- LTIP829A LTIP829A LTIP829A LTIP829A LTIP829A LT IP829 A LTIP829 A LT IP829A LT IP829 A LTIP829 A LT IP829A LT IP829 A LTIP829 A LT IP829A LT IP829 A LTIP829 A LT IP829A
- Authority
- LT
- Lithuania
- Prior art keywords
- alkyl
- morpholino
- propyl
- amino
- alkyleneimino
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- GOIPIEMTOZZMNH-UHFFFAOYSA-N 4-morpholin-4-yl-6-propyl-1,3,5-triazin-2-amine Chemical class CCCC1=NC(N)=NC(N2CCOCC2)=N1 GOIPIEMTOZZMNH-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004171 alkoxy aryl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000006213 aryl hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000003106 haloaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/08—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Cosmetics (AREA)
Abstract
New 2-amino-4-morpholino-6-propyl-1,3,5-triazines having the formula <IMAGE> (I) wherein R1 is hydrogen, alkyl, aralkyl or acetyl, R2 is hydroxyl, hydroxyalkyl, alkoxyalkyl, dialkylamino, arylhydroxyalkyl, (hydroxy-cycloalkyl)alkyl, alkanoyloxyalkyl, benzoyloxyalkyl, phenylacetyloxyalkyl, aminocarbonyloxyalkyl, COR3 or CONR4R5, or NR1R2=(hydroxyalkyl)alkyleneimino, R3=alkyl, aryl, haloaryl, alkylaryl, alkoxyaryl, aralkyl or aryloxy, R4=R5=hydrogen or alkyl, alkyl, alkoxy and alkanoyloxy having 1 to 4 carbon atoms, cycloalkyl and alkyleneimino having 4 to 6 carbon atoms. Moreover, when R1 is acetyl, R2 is acetoxyalkyl. Processes for the preparation thereof and pharmaceutical compositions containing the same are also given. In particular, these compounds are useful for the treatment of cognitive and behavioral disorders associated with aging and dementia syndromes, e.g. those associated with Alzheimer's disease.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888819493A GB8819493D0 (en) | 1988-08-16 | 1988-08-16 | 2-amino-4-morpholino-6-propyl-1 3 5-triazines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTIP829A true LTIP829A (en) | 1995-02-27 |
| LT3601B LT3601B (en) | 1995-12-27 |
Family
ID=10642235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTIP829A LT3601B (en) | 1988-08-16 | 1993-08-03 | Derivatives of 2-amino-4-morpholino-6-propyl-1,3,5,-triazine and salts thereof |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US4956367A (en) |
| EP (1) | EP0356413B1 (en) |
| JP (1) | JPH02108675A (en) |
| KR (1) | KR0136108B1 (en) |
| AT (1) | ATE72241T1 (en) |
| AU (1) | AU614247B2 (en) |
| CA (1) | CA1317944C (en) |
| CY (1) | CY1709A (en) |
| DE (1) | DE68900794D1 (en) |
| DK (1) | DK171698B1 (en) |
| ES (1) | ES2038849T3 (en) |
| FI (1) | FI102065B1 (en) |
| GB (1) | GB8819493D0 (en) |
| GR (1) | GR3004267T3 (en) |
| HK (1) | HK95693A (en) |
| HU (1) | HUT58087A (en) |
| IE (1) | IE61205B1 (en) |
| IL (1) | IL91243A (en) |
| LT (1) | LT3601B (en) |
| MY (1) | MY105008A (en) |
| NO (1) | NO179206C (en) |
| NZ (1) | NZ230290A (en) |
| PL (2) | PL161591B1 (en) |
| PT (1) | PT91438B (en) |
| RU (3) | RU1806142C (en) |
| SG (1) | SG27893G (en) |
| UA (1) | UA11064A (en) |
| ZA (1) | ZA896222B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9024617D0 (en) * | 1989-12-05 | 1991-01-02 | Ici Plc | Heterocyclic compounds |
| GB9008818D0 (en) * | 1990-04-19 | 1990-06-13 | Ici Plc | Amine derivatives |
| IT1240690B (en) * | 1990-04-30 | 1993-12-17 | Ciba Geigy Ag | PIPERDIN-TRIAZIN COMPOUNDS SUITABLE FOR USE AS STABILIZERS FOR ORGANIC MATERIALS |
| GB9116039D0 (en) * | 1991-07-25 | 1991-09-11 | Ucb Sa | Substituted cyclopropylamino-1,3,5-triazines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3549755A (en) * | 1968-03-27 | 1970-12-22 | Shell Oil Co | Use of 2-trichloromethyl-4-morpholinoor piperazino-6-substituted-s-triazines for inducing depressant effects in animals |
| JPS4969688A (en) * | 1972-11-02 | 1974-07-05 | ||
| FR2262512A1 (en) * | 1974-03-01 | 1975-09-26 | Synthelabo | 2,4,6-Tri-substd. -1,3,5-triazines - with analgesic and psychotropic activity |
-
1988
- 1988-08-16 GB GB888819493A patent/GB8819493D0/en active Pending
-
1989
- 1989-07-28 EP EP89870120A patent/EP0356413B1/en not_active Expired - Lifetime
- 1989-07-28 AT AT89870120T patent/ATE72241T1/en not_active IP Right Cessation
- 1989-07-28 DE DE8989870120T patent/DE68900794D1/en not_active Expired - Lifetime
- 1989-07-28 ES ES198989870120T patent/ES2038849T3/en not_active Expired - Lifetime
- 1989-08-07 FI FI893714A patent/FI102065B1/en not_active IP Right Cessation
- 1989-08-08 US US07/390,878 patent/US4956367A/en not_active Expired - Fee Related
- 1989-08-08 IL IL9124389A patent/IL91243A/en not_active IP Right Cessation
- 1989-08-09 MY MYPI89001088A patent/MY105008A/en unknown
- 1989-08-09 CA CA000607834A patent/CA1317944C/en not_active Expired - Fee Related
- 1989-08-11 PT PT91438A patent/PT91438B/en not_active IP Right Cessation
- 1989-08-11 PL PL89283603A patent/PL161591B1/en unknown
- 1989-08-11 PL PL1989281021A patent/PL161161B1/en unknown
- 1989-08-14 DK DK398189A patent/DK171698B1/en active
- 1989-08-14 NZ NZ230290A patent/NZ230290A/en unknown
- 1989-08-15 JP JP1210547A patent/JPH02108675A/en active Pending
- 1989-08-15 RU SU894614758A patent/RU1806142C/en active
- 1989-08-15 NO NO893279A patent/NO179206C/en unknown
- 1989-08-15 IE IE261989A patent/IE61205B1/en not_active IP Right Cessation
- 1989-08-15 AU AU39917/89A patent/AU614247B2/en not_active Ceased
- 1989-08-15 ZA ZA896222A patent/ZA896222B/en unknown
- 1989-08-15 HU HU894192A patent/HUT58087A/en unknown
- 1989-08-16 KR KR1019890011696A patent/KR0136108B1/en not_active Expired - Fee Related
- 1989-12-21 UA UA4742645A patent/UA11064A/en unknown
- 1989-12-21 RU SU894742645A patent/RU1822403C/en active
-
1990
- 1990-08-20 RU SU904830673A patent/RU1838312C/en active
-
1992
- 1992-04-02 GR GR920400622T patent/GR3004267T3/el unknown
-
1993
- 1993-03-16 SG SG278/93A patent/SG27893G/en unknown
- 1993-08-03 LT LTIP829A patent/LT3601B/en not_active IP Right Cessation
- 1993-09-16 HK HK956/93A patent/HK95693A/en not_active IP Right Cessation
-
1994
- 1994-01-14 CY CY170994A patent/CY1709A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL91244A0 (en) | Pharmaceutical compositions containing 2-amino-4-morpholino-6-propyl-1,3,5-triazines | |
| EP0222693A3 (en) | 3-oxadiazolyl and 3-carboxylic-acid beta-carboline derivatives, their preparation and their use as medicaments | |
| LTIP829A (en) | Derivatives of 2-amino-4-morpholino-6-propyl-1,3,5,-triazine and salts thereof | |
| BR9916046A (en) | Compound, pharmaceutical composition, and processes for inhibiting the replication of a herpes virus and for treating a patient suffering from a herpes virus infection | |
| JPS6461466A (en) | Derivatives of ureylene, 2,4-triminopyrimidine- 3-oxide, preparation and use for cosmetic and pharmacological composition | |
| HUT70761A (en) | Alkyl derivatives of trazodone having action for central nervous system, pharmaceutical compositions for preparing thereof | |
| IL92280A0 (en) | Oxime ether derivatives,their preparation and fungicidal compositions containing them | |
| GR3017916T3 (en) | 3,4-Disubstituted phenyl-heterocycles and their use. | |
| IL90043A0 (en) | Sulfonanilides,their preparation and pharmaceutical compositions containing them | |
| ZA891108B (en) | Basic-substituted 5-halo-thienoisothiazol-3(2h)-one 1,1-dioxides,a process for the preparation thereof,and pharmaceutical preparations containing these compounds | |
| DE3862660D1 (en) | 2,3-DIHYDRO-2-OXO-3-BENZOFURANYL ACETIC ACID DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM. | |
| DE68922596D1 (en) | 3- (3-Ethyl-1,2,4-oxadiazol-5-yl) -1-azabicycloheptane, process for its preparation and pharmaceutical preparations containing it. | |
| ATE4384T1 (en) | BENZOTHIOPYRANO(2,3-C)PYRIDINES AND THEIR ACID ADDITION SALTS, THEIR PREPARATION, THEIR USE AS MEDICINAL PRODUCTS AND COMPOSITIONS CONTAINING THESE COMPOUNDS. | |
| BG50775A1 (en) | Derivatives of 2, 3- dimethyl- 1- phenyl- 4- (2- phenylmorpholinomethyl)- 5- pyrazolones and method for their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 19990803 |